Roche’s Tecentriq snags FDA label expansion in type of colon cancer
Roche has notched a twelfth indication on the belt of its blockbuster cancer therapy Tecentriq (atezolizumab), following the US Food…
All articles by Annabel Kartal Allen
Annabel Kartal Allen
Annabel Kartal-Allen is a reporter for Clinical Trials Arena, Pharmaceutical Technology and Medical Device Network based in London, UK. Annabel holds interests in oncology, neurology and metabolic diseases. She has previous experience reporting for both the pharmaceutical and nutraceutical industries, and holds a BSc in Biology from the University of Sussex. Contact Annabel
-
-
Viatris makes foray into non-opioid pain space on $1.65bn Pacira buyout
California-based healthcare company Viatris has inked a billion-dollar deal to acquire Pacira BioSciences and its non-opioid pain management therapies –…
-
KymaThera pulls in $80m to bring breast cancer drug to clinic
San Diego-based biotech KymaThera has banked $80m in a Series B funding round to bring a breast cancer drug to…
-
Shionogi bolsters rare disease portfolio with $2bn IntraBio buyout
Japanese pharma company, Shionogi, is set to acquire IntraBio in a multibillion-dollar deal, adding neurological and movement disorder drug, Aqneursa…
-
Lilly deepens ties with Gate Bioscience in $870m deal expansion
Eli Lilly has expanded its partnership and licensing agreement with California-based biotech, Gate Bioscience, to develop molecular gate therapies targeting…
-
CSL and Alentis ink $1.5bn partnership to progress antifibrotic drug
CSL has penned an exclusive collaboration deal with Swiss biotech, Alentis Therapeutics, which will see the pair join forces to…
-
Scientists claim Nobel Prize for approach behind light-activated gene therapy
A trio of German and American scientists have won this year’s Nobel Prize in Physiology or Medicine for their discovery…
-
GLP-1RA non-responders: tackling a hidden challenge behind the obesity epidemic
In recent years, the notoriety and uptake of incretin-based therapies such as glucagon-like peptide-1 receptor agonists (GLP-1RAs) has skyrocketed, with…
-
AstraZeneca deepens Summit ties on ADC-bispecific cancer combo testing pact
AstraZeneca and Daiichi Sankyo have partnered with Summit Therapeutics to explore the potential of their co-developed antibody-drug conjugate (ADC), Datroway…
-
Novartis bets on autoimmune BiTEs through $7.8bn Abogen deal
Novartis has become the latest big pharma player to bet on the bispecific T-cell engager (BiTE) modality by inking a…